title: [Progressive increase of serum circulating immune complexes and its significance in patients during the progression from chronic hepatitis B to hepatocellular carcinoma].
abstract: OBJECTIVE
  To investigate the significance of increasing circulating immune complex (CIC) in patients during the progression from chronic hepatitis B to hepatocellular carcinoma (HCC).
  
  
  METHODS
  Serum levels of CIC from 20 hospitalized patients diagnosed by pathology with primary HCC, and 13 with hepatic hemangioma, and from 45 subjects with chronic HBV infection who finally developed into HCC (45 cases), and age- and gender-matched 45 subjects who kept the chronic HBV infection after consecutively followed up for 10 - 13 years by June of 2009 were quantified by ELISA. The serum levels of anti liver-kidney microsomal (anti LKM-1) antibodies were also measured by ELISA, and that of HBV-DNA were quantified by Taqman probe-based real time PCR in the followed up chronic HBV infection subjects. In the 45 chronic HBV subjects who finally developed into HCC and the 45 controls, serum samples were collected and determined at 3 time points: the baseline when the subjects were recruited, the middle point during the follow-up, and the end of follow-up.
  
  
  RESULTS
  The serum level of CIC was significantly higher in the 20 HCC patients than that in the 13 hemangioma cases (P < 0.001). When HCC was diagnosed, the CIC concentration was significantly higher than that in the baselines (P < 0.001) in the 45 chronic HBV subjects who finally developed into HCC after the consecutively follow-up for 5 - 13 years. Of them, 36 patients (80.0%) showed progressively increased CIC during the follow-up (P < 0.001). In the controls, the CIC levels were kept relatively stable during the follow-up. Among them, 17 patients (37.8%) showed CIC slightly increased (P = 0.046). Kaplan-Meier survival analysis indicated that elevated serum CIC during the follow-up increased cumulative HCC incidence (HR = 2.77, 95%CI 1.47 - 5.22). In addition, the serum levels of anti-LKM-1 and HBV-DNA were also significantly higher in the patients who finally progressed into HCC than that in the controls and maintained at a high level during the follow-up tested at all the 3 time points. Further analysis indicated that the serum level of CIC was correlated with that of serum HBV-DNA only when HCC was diagnosed (r = 0.344, P = 0.026).
  
  
  CONCLUSIONS
  Progressive increase of serum CIC level may be one of risk factors reflecting HCC development from chronic HBV infection.
authors.affiliation: State Key Laboratory of Molecular Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Du
authors.forename: Ping
authors.initials: P
authors.lastname: Tian
authors.forename: Tao-yang
authors.initials: TY
authors.lastname: Chen
authors.forename: Jian-xiong
authors.initials: JX
authors.lastname: Wu
authors.forename: Jin-bing
authors.initials: JB
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Wei
authors.forename: Li-ming
authors.initials: LM
authors.lastname: Wang
authors.forename: Li-guo
authors.initials: LG
authors.lastname: Liu
authors.forename: Wan-sheng
authors.initials: WS
authors.lastname: Ji
authors.forename: Chun-feng
authors.initials: CF
authors.lastname: Qu
mesh_terms: D000936:Antigen-Antibody Complex / Q000097:blood*; D001323:Autoantibodies / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000821:virology*; D004279:DNA, Viral / Q000097:blood; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006391:Hemangioma / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000276:immunology; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D000936:Antigen-Antibody Complex; D001323:Autoantibodies; D004279:DNA, Viral; C060729:anti-liver kidney microsome antibody